S-1/A: Cortigent Eyes $15 Million IPO to Advance Neurostimulation Technologies

Cortigent, a neurostimulation technology company, aims to raise approximately $15 million through an initial public offering to fund the development of its Orion visual prosthesis and stroke recovery system.

Summary

• Cortigent, Inc., a company focused on developing neurostimulation systems, is seeking to raise capital through an IPO to further its research and development efforts.
• The company's lead product, the Orion Visual Cortical Prosthesis System, aims to restore partial vision to individuals with profound blindness.
• Cortigent is also developing a stroke recovery system designed to improve arm and hand function in partially paralyzed stroke patients.
• The company intends to use the net proceeds from the IPO, estimated at $12.95 million (or $15.02 million if the underwriters exercise their over-allotment option in full), primarily for Orion research studies, manufacturing devices for clinical trials, and repaying amounts owed to its parent company, Vivani Medical, Inc.
• Cortigent has applied to list its common stock on the Nasdaq Capital Market under the symbol CRGT.
• Vivani Medical, Inc., will beneficially own approximately 77% of the voting power of Cortigent's common stock after the completion of this offering.
• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future.
• Cortigent is targeting to commence a pivotal clinical trial for Orion by mid-2026, complete it by mid-2028, and launch in early 2029, and to commence a pivotal clinical trial for the stroke recovery system in late 2027, complete it by mid-2029, and launch in late 2029.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the potential of Cortigent's technology and the significant risks and challenges the company faces. The sentiment is cautiously optimistic, reflecting the high-risk, high-reward nature of investing in early-stage medical device companies.

Positives

• Cortigent's Orion system has received Breakthrough Device designation from the FDA, which is intended to accelerate medical device development, assessment, and review.
• The company has an extensive intellectual property estate with rights to 213 issued U.S. patents and 24 issued European patents.
• Cortigent's technology has the potential to address significant unmet medical needs in artificial vision and stroke recovery.
• The company has completed an Early Feasibility Study of Orion, with positive efficacy data reported for square localization, direction of motion, and grating visual acuity.
• The company is planning to work with the FDA to gain agreement on the additional clinical studies that will be required to secure marketing approval for Orion.

Negatives

• Cortigent currently has no commercial products or product revenue and may never become profitable.
• The company has a history of operating losses and expects to continue incurring losses for the foreseeable future.
• Clinical development of medical devices involves a lengthy and expensive process with an uncertain outcome.
• The company will require substantial additional capital to support its clinical trials and growth plans, and such capital may not be available on acceptable terms.
• Vivani will have the ability to control the outcome of matters submitted to our stockholders for approval, including the election of our directors and the approval of significant corporate transactions.

Risks

• Cortigent's commercial and financial success depends on its future products being accepted in the market.
• The company may face substantial competition in the future and may not be able to keep pace with rapid technological changes.
• Results from Cortigent's limited initial trials may not be predictive of future trial results.
• The company may be subject to litigation in the operation of its business.
• Any failure or delay in completing clinical trials could adversely affect its business.
• If Cortigent fails to recruit highly skilled personnel, its ability to develop and commercialize new products will be impaired.
• If Cortigent or its licensors are unable to protect its/their intellectual property, then Cortigent's financial condition, results of operations and the value of Cortigent's technology and products could be adversely affected.
• Cortigent is subject to stringent domestic and foreign medical device regulation and any unfavorable regulatory action may materially and adversely affect Cortigent's financial condition and business operations.
• Any revenue from sales of Cortigent products will be dependent upon the pricing and reimbursement guidelines adopted in each country, and if pricing and reimbursement levels are inadequate to achieve profitability, Cortigent's operations will suffer.

Future Outlook

Cortigent plans to work with the FDA to gain agreement on additional clinical studies required for marketing approval of Orion, targeting pivotal trial commencement by mid-2026 and potential US market launch in early 2029. The company also intends to commence an Early Feasibility Study for the stroke recovery system in mid-2026, with a pivotal trial targeted for late 2027 and potential launch in late 2029.

Industry Context

Cortigent operates in the competitive medical device industry, facing competition from companies developing visual prostheses and stroke rehabilitation devices. Competitors include Pixium Vision SA, Nano Retina Inc., Bionic Vision Technologies, MicroTransponder Inc., and others. The company believes its targeted neurostimulation technology has the potential to deliver superior results compared to existing therapies.

Comparison to Industry Standards

• The document mentions several competitors in the visual prosthesis field, including Pixium Vision SA, Nano Retina Inc., and Bionic Vision Technologies.
• In the field of stroke rehabilitation, MicroTransponder Inc.'s Vivistim system is mentioned as a competitor.
• Northstar Neuroscience's previous work in cortical stimulation for stroke recovery is referenced as a basis for Cortigent's approach.
• The document does not provide a direct comparison of Cortigent's results to specific industry benchmarks or standards, but it highlights the potential market size and reimbursement levels similar to the Argus II device.

Related Party Transactions

• Prior to this offering Cortigent has been a wholly owned subsidiary of Vivani Medical, Inc.
• Upon completion of this offering, Vivani will beneficially own approximately 77% of the voting power of our common stock.
• Adam Mendelsohn, Chairman of the Board of Cortigent, serves as chief executive officer and a director of Vivani.
• Cortigent and Vivani have entered into a Transition Funding, Support and Services Agreement in March 2023 by which Vivani will advance funds and provide or cause to be provided the funding and support services that can sustain Cortigents operations from January 2023, until the earlier of December 31, 2024 or receipt of proceeds from this offering.
• In August 2023 Vivani and we amended that agreement to provide for (i) repayment of $1.5 million from proceeds of this offering and (ii) issuance of a five year promissory note requiring repayment of $2 million at five percent per year upon maturity of the promissory note.
• By this amendment Vivani also agreed that we shall not be obligated to repay any funding support payments that it made to us which exceed a cumulative $3.5 million.

Stakeholder Impact

• Shareholders: Potential for capital appreciation if Cortigent's products are successful, but also risk of dilution and loss of investment.
• Employees: Opportunity to work on innovative technologies, but also risk of job insecurity due to the company's financial situation.
• Patients: Potential to benefit from new treatments for blindness and stroke recovery, but also risk of adverse events and limited efficacy.
• Suppliers: Opportunity to provide materials and services to Cortigent, but also risk of payment delays or contract termination.
• Creditors: Risk of default on debt obligations if Cortigent is unable to generate sufficient revenue.

Next Steps

• Manufacture and validate new Orion devices for a planned pivotal clinical trial.
• Commence the pivotal trial for Orion by or about mid 2026.
• Complete the pivotal trial for Orion by approximately mid 2028.
• Obtain FDA clearance and launch Orion on the US market in early 2029.
• Manufacture modified clinical trial devices for the planned Early Feasibility Study (EFS) for the stroke recovery system.
• Commence the EFS for the stroke recovery system in mid 2026.
• Commence a pivotal clinical trial for the stroke recovery system in late 2027.
• Complete the pivotal clinical trial for the stroke recovery system by mid 2029.
• Launch the stroke recovery system in late 2029.

Key Dates

Keywords

neurostimulation, Orion, stroke recovery, artificial vision, clinical trials, FDA approval, medical device, Cortigent, IPO, blindness